Our overall goals are to identify determinants of drug clearance to improve medication therapy for older patients. Algorithms to estimate age, sex, and race effects on renal drug clearance exist. No such algorithms exist for non-renal drug clearance. Because the majority of non-renally cleared medications are metabolized by CYP3A, we began studies with drugs cleared by this enzyme. We have completed the first studies of steady-state CYP-mediated drug clearance in patient populations that include significant numbers of women, the very old (>80 years of age), and residents of assisted living and long-term care facilities. We used the population approach that allows sparse sampling from individuals. To our surprise, clearance rates were among the highest in patients from ages 65-90, and in the oldest nursing home residents. The age-related findings were consistent for three CYP3A substrate drugs that varied widely in pharmacological properties (bioavailabiltiy and transporter affinity). We also found faster clearance in women compared to men and identified covariates (smoking, alcohol intake) that affected clearance in men, but were not present in women, or the oldest patients. Clearance rates also varied by race with whites>blacks and >Hispanics. Dietary analyses suggest vitamin D intake influences CYP3A clearance rates. These results suggest studies of physiologic aging excluding the very old, women, and minority groups may not reflect clearance characteristics in older patients Ithat receive medications. We propose population studies of a CYP3A substrate, atorvastatin, in diverse clinical populations with an interventional study to investigate a potential mechanism for preserved clearance rates in older patients, and the first population studies of CYP2C19- mediated clearance of lansoprazole to investigate age, sex, and genotype (race) effect on steady-state clearance rates of this important polymorphic enzyme. The potential impact of these findings on the care of the growing number of very old patients, especially understudied women and minority groups, is great.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG015982-10
Application #
7600376
Study Section
Special Emphasis Panel (ZRG1-ASG (01))
Program Officer
Nayfield, Susan G
Project Start
1999-09-01
Project End
2010-09-15
Budget Start
2009-05-01
Budget End
2010-09-15
Support Year
10
Fiscal Year
2009
Total Cost
$237,462
Indirect Cost
Name
Jewish Home of San Francisco
Department
Type
DUNS #
020004693
City
San Francisco
State
CA
Country
United States
Zip Code
94112
Schwartz, Janice B; Gallagher, J Christopher; Jorde, Rolf et al. (2018) Determination of Free 25(OH)D Concentrations and Their Relationships to Total 25(OH)D in Multiple Clinical Populations. J Clin Endocrinol Metab 103:3278-3288
Schwartz, Janice B; Moore, Kelly L; Yin, Michael et al. (2014) Relationship of vitamin D, HIV, HIV treatment, and lipid levels in the Women's Interagency HIV Study of HIV-infected and uninfected women in the United States. J Int Assoc Provid AIDS Care 13:250-9
Schwartz, J B; Lai, J; Lizaola, B et al. (2014) A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations. J Clin Endocrinol Metab 99:1631-7
Schwartz, J B; Lai, J; Lizaola, B et al. (2014) Variability in free 25(OH) vitamin D levels in clinical populations. J Steroid Biochem Mol Biol 144 Pt A:156-8
Kane, Lynn; Moore, Kelly; Lütjohann, Dieter et al. (2013) Vitamin D3 effects on lipids differ in statin and non-statin-treated humans: superiority of free 25-OH D levels in detecting relationships. J Clin Endocrinol Metab 98:4400-9
Schwartz, Janice B; Kane, Lynn; Moore, Kelly et al. (2011) Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. J Am Med Dir Assoc 12:633-8
Schwartz, J B (2009) Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther 85:198-203
Schwartz, J B; Verotta, D (2009) Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. Clin Pharmacol Ther 86:497-502
Schwartz, J B (2007) The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 82:87-96
Schwartz, Janice B (2006) Erythromycin breath test results in elderly, very elderly, and frail elderly persons. Clin Pharmacol Ther 79:440-8

Showing the most recent 10 out of 25 publications